直接抗病毒药物未增加慢性HCV感染者肝细胞癌的发生率

曾庆磊; 余祖江

doi:10.3969/j.issn.1001-5256.2017.06.011

直接抗病毒药物未增加慢性HCV感染者肝细胞癌的发生率

DOI: 10.3969/j.issn.1001-5256.2017.06.011

郑州大学第一附属医院感染病科

详细信息

中图分类号: R512.63;R735.7
计量
- 文章访问数: 2179
- HTML全文浏览量: 16
- PDF下载量: 461
- 被引次数: 0
出版历程
- 出版日期: 2017-06-20

Whether antiviral therapy can reduce the incidence of hepatocellular carcinoma in patients with chronic HCV infection

摘要

摘要: 2010年研究发现慢性HCV感染者经治疗获得持续病毒学应答意味着治愈,全球范围内IFN联合利巴韦林的总体治愈率为60%左右,中国的真实世界研究结果为71.1%。2013年以后,美国率先上市针对HCV的直接抗病毒药物(DAA),治愈率提高至接近100%。然而,近期有研究发现应用DAA后肝细胞癌的发生率有所升高,DAA是不是元凶目前仍有争议。笔者认为这主要是DAA的适应证覆盖了更多且疾病程度更重的终末期丙型肝炎患者所致,而这部分患者本身就是肝细胞癌的高危人群;亦不能完全排除DAA可导致机体抑癌免疫状态发生改变,未来需要从分子水平进行确证。
- 肝炎,丙型,慢性 /
- 癌,肝细胞 /
- 抗病毒药
Abstract: In 2010, studies found that achievement of sustained virologic response after treatment in patients with chronic HCV infection meant cure; the overall cure rate of interferon combined with ribavirin around the world was about 60%, and the result of real-world study in China was 71. 1%. In 2013, the US took the lead in launching the direct-acting antiviral agents (DAAs) for HCV, and the cure rate was increased to almost 100%. However, recent studies have found that the incidence of hepatocellular carcinoma (HCC) tends to increase after the application of DAAs, and there are still controversies over whether DAAs are the major cause of this phenomenon. In our opinion, this phenomenon is caused by the fact that the indications for DAAs cover more end-stage hepatitis C patients who are intrinsically the high-risk population of HCC; however, it cannot be excluded that DAAs may lead to the change in the body's antitumor immune status. Studies are needed in the future to examine this issue at the molecular level.
- hepatitis C, chronic /
- carcinoma, hepatocellular /
- antiviral agents

HTML全文

参考文献(34)

[1]WANG FS, FAN JG, ZHANG Z, et al.The global burden of liver disease:the major impact of China[J].Hepatology, 2014, 60 (6) :2099-2108.

[2]CUI Y, JIA J.Update on epidemiology of hepatitis B and C in China[J].J Gastroenterol Hepatol, 2013, 28 (Suppl 1) :7-10.

[3]WEI L, LOK AS.Impact of new hepatitis C treatments in different regions of the world[J].Gastroenterology, 2014, 146 (5) :1145-1150, e1141-e1144.

[4]ZENG QL, FENG GH, ZHANG JY, et al.Risk factors for liverrelated mortality in chronic hepatitis C patients:a deceased caseliving control study[J].World J Gastroenterol, 2014, 20 (18) :5519-5526.

[5]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2016[J].J Hepatol, 2017, 66 (1) :153-194.

[6]ZENG QL, ZHANG JY, ZHANG Z, et al.Sofosbuvir and ABT-450:terminator of hepatitis C virus?[J].World J Gastroenterol, 2013, 19 (21) :3199-3206.

[7]SWAIN MG, LAI MY, SHIFFMAN ML, et al.A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin[J].Gastroenterology, 2010, 139 (5) :1593-1601.

[8]LEE MH, YANG HI, LU SN, et al.Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma:long-term predictors from a community-based cohort study[J].J Clin Oncol, 2010, 28 (30) :4587-4593.

[9]LEE MH, YANG HI, YUAN Y, et al.Epidemiology and natural history of hepatitis C virus infection[J].World J Gastroenterol, 2014, 20 (28) :9270-9280.

[10]LEE MH, YANG HI, LU SN, et al.Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma[J].Int J Cancer, 2014, 135 (5) :1119-1126.

[11]RAO HY, LI H, CHEN H, et al.Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China:an interim analysis from the CCgenos study[J].J Gastroenterol Hepatol, 2017, 32 (1) :244-252.

[12]International Interferon-alpha Hepatocellular Carcinoma Study Group.Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma:a retrospective cohort study[J].Lancet, 1998, 351 (9115) :1535-1539.

[13]LEE SH, JIN YJ, SHIN JY, et al.Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs[J].Medicine (Baltimore) , 2017, 96 (1) :e5321.

[14]JANJUA NZ, CHONG M, KUO M, et al.Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada[J].J Hepatol, 2017, 66 (3) :504-513.

[15]SHIRATORI Y, ITO Y, YOKOSUKA O, et al.Antiviral therapy for cirrhotic hepatitis C:association with reduced hepatocellular carcinoma development and improved survival[J].Ann Intern Med, 2005, 142 (2) :105-114.

[16]IMAI Y, KASAHARA A, TANAKA H, et al.Interferon therapy for aged patients with chronic hepatitis C:improved survival in patients exhibiting a biochemical response[J].J Gastroenterol, 2004, 39 (11) :1069-1077.

[17]EL-SERAG HB, KANWAL F, RICHARDSON P, et al.Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection[J].Hepatology, 2016, 64 (1) :130-137.

[18]ZENG QL, LI B, ZHANG XX, et al.Clinical model for predicting hepatocellular carcinomas in patients with post-sustained virologic responses of chronic hepatitis C:a case control study[J].Gut Liver, 2016, 10 (6) :955-961.

[19]van DER MEER AJ, WEDEMEYER H, FELD JJ, et al.Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population[J].JAMA, 2014, 312 (18) :1927-1928.

[20]RUTTER K, STATTERMAYER AF, BEINHARDT S, et al.Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C[J].Aliment Pharmacol Ther, 2015, 41 (6) :521-531.

[21]DI MARCO V, CALVARUSO V, FERRARO D, et al.Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension[J].Gastroenterology, 2016, 151 (1) :130-139, e132.

[22]LU M, LI J, RUPP LB, et al.Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma[J].J Viral Hepat, 2016, 23 (9) :718-729.

[23]KOZBIAL K, MOSER S, SCHWARZER R, et al.Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment[J].J Hepatol, 2016, 65 (4) :856-858.

[24]REIG M, MARINO Z, PERELLO C, et al.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy[J].J Hepatol, 2016, 65 (4) :719-726.

[25]CONTI F, BUONFIGLIOLI F, SCUTERI A, et al.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals[J].J Hepatol, 2016, 65 (4) :727-733.

[26]NAULT JC, COLOMBO M.Hepatocellular carcinoma and direct acting antiviral treatments:controversy after the revolution[J].J Hepatol, 2016, 65 (4) :663-665.

[27]ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 Cir Vir and CO23 CUPILT cohorts) .Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma:Data from three ANRS cohorts[J].J Hepatol, 2016, 65 (4) :734-740.

[28]CHEUNG MC, WALKER AJ, HUDSON BE, et al.Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis[J].J Hepatol, 2016, 65 (4) :741-747.

[29]ZENG QL, LI CX, ZHANG DW, et al.Letter:safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12 weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV[J].Aliment Pharmacol Ther, 2016, 43 (7) :842-843.

[30]ZENG QL, LI ZQ, LIANG HX, et al.Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs:too alarming?[J].J Hepatol, 2016, 65 (5) :1068-1069.

[31]CALLEJA JL, CRESPO J, RINCON D, et al.Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection:results from a Spanish real world cohort[J].J Hepatol, 2017.[Epub ahead of print]

[32]MEISSNER EG, WU D, OSINUSI A, et al.Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome[J].J Clin Invest, 2014, 124 (8) :3352-3363.

[33]MEISSNER EG, KOHLI A, VIRTANEVA K, et al.Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis[J].J Viral Hepat, 2016, 23 (7) :496-505.

[34]SERTI E, CHEPA-LOTREA X, KIM YJ, et al.Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function[J].Gastroenterology, 2015, 149 (1) :190-200, e192.

施引文献

资源附件(0)

访问统计